• OncoZenge registered 772,797 new shares from a directed share issue to Sichuan Yangtian Bio-Pharmaceutical following SEK 5 million payment.
• Subscription price set at SEK 6.47 per share; placement targets total proceeds of about SEK 15.1 million.
• Share count rose to 14,820,865 from 14,048,068; dilution from the registered tranche estimated at about 5.2%.
• Remaining 1,562,026 shares stay unregistered pending about SEK 10.1 million; payment deadline extended to Aug. 28, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncozenge AB published the original content used to generate this news brief on August 21, 2026, and is solely responsible for the information contained therein.